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BRIEF CLINICAL OBSERVATIONS 
NON-ALTITUDE-RELATED 
SPLENIC INFARCTION IN A 
PATIENT WITH SICKLE CELL 
TRAIT 
Splenic infarction is a well-docu- 
mented complication of sickle cell 
anemia, sickle cell-hemoglobin C 
disease, and sickle cell-P-thalasse- 
mia disease. Many of these cases 
have been associated with exposure 
to high altitudes [l]. There have 
also been reported cases of high- 
altitude-related splenic infarction 
in persons with sickle cell trait (he- 
moglobin AS), usually considered 
to be a benign hemoglobinopathy 
[1,2]. Splenic infarction not related 
to high-altitude exposure in per- 
sons with sickle cell trait has been 
reported five times previously [2- 
6]. We report an additional case of 
non-altitude-related splenic in- 
farction in a patient with sickle cell 
trait, and review the literature in 
an attempt to better understand 
this disorder. 
An obese 27-year-old man of 
Middle Eastern descent was in his 
usual state of health until July 
1987, when he was awakened by the 
abrupt onset of nausea and vomit- 
ing. This was followed by the devel- 
opment of severe left upper quad- 
rant abdominal pain that radiated 
to the back. The pain was nonposi- 
tional, did not vary with respira- 
tion, increased postprandially, and 
was associated with mild dyspnea. 
He was treated with ampicillin but 
had no improvement. Because of 
increasing pain, he was hospital- 
ized with a temperature of 38.3”C, 
hemoglobin level of 8.5 mmol/L, 
hematocrit of 0.39, total leukocyte 
count of 24.5 X log/L with normal 
differential, and platelet count of 
322 X log/L. Serum chemistries, 
serum lipase, rheumatoid factor, 
antinuclear antibody, cold aggluti- 
nins, antimitochondrial antibody, 
and Monospot@ test result were 
normal. Abnormal findings on lab- 
oratory studies included the fol- 
lowing: erythrocyte sedimentation 
rate 42 mm/hour, uric acid 0.6 
mmol/L, and lactate dehydroge- 
nase 3,317 nmol/second/L with in- 
creased LDHs fraction. Past medi- 
cal and family histories were non- 
contributory. 
Chest radiography revealed a tri- 
angular density that was believed 
to be a combination of infiltrate 
and atelectasis/consolidation, with 
a small left pleural effusion. Room- 
air arterial blood gas studies re- 
vealed a pH of 7.45, oxygen tension 
of 73 mm Hg, carbon dioxide ten- 
sion of 37 mm Hg, and bicarbonate 
level of 25 mEq/L. Thoracentesis 
revealed a total leukocyte count of 
8.99 X log/L with 93% polymorpho- 
nuclear leukocytes and 2% mono- 
cytes, glucose greater than 33.6 
mmol/L, lactate dehydrogenase 
303,000 nmollsecondll, protein 
180 g/L, negative bacterial and 
acid-fast bacilli smears and cul- 
tures, and negative results of cyto- 
logic study. Evaluation of Hemoc- 
cult-positive stool included a bari- 
um enema, results of which were 
normal. 
Because of persistent left upper 
quadrant pain, further studies 
were performed. A retrograde py- 
elogram, intravenous pyelogram, 
cystoscopy, and renal ultrasound 
failed to explain the etiology of his 
pain. An indium scan revealed in- 
creased activity in the right lung 
n and within the midline anterior 
chest in a linear pattern; there was 
no activity within the spleen. Find- 
ings on a liver/spleen scan were sig- 
nificant for nonvisualization of the 
spleen. 
The patient’s platelet count 
gradually increased to 1,100 X log/ 
L on the 10th hospital day, with a 
persistent mild anemia and a per- 
sistent leukocytosis of 24.0 X log/ 
L. His serum lactate dehydroge- 
nase level also increased to 5,267 
nmol/second/L. Because of persis- 
tent thrombocytosis of greater 
than 1 X 1012 (1,440 x log/L) and 
the leukocytosis, the patient was 
transferred to the University of 
Michigan Medical Center 
(UMMC) for further evaluation. 
Upon admission to UMMC, 
physical examination revealed the 
patient to be in no apparent dis- 
tress with a temperature of 37.6”C. 
His lung fields were clear. Cardiac 
examination demonstrated no 
murmurs. Abdominal examination 
revealed a soft, obese abdomen 
without organomegaly or masses 
and normal active bowel sounds. 
There was no clinical evidence for 
the presence of obesity-associated 
hypoventilation of pulmonary em- 
bolus. Hemoglobin was 8.2 mmol/ 
L, hematocrit was 0.40, total leuko- 
cyte count was 25.7 X log/L with 
55% segmented forms, 3% bands, 
23% lymphocytes, and 19% mono- 
cytes, and platelet count was 1,000 
X log/L. Findings on other labora- 
tory studies were unremarkable, 
except for aspartate aminotrans- 
ferase 667 nmol/second/L, alanine 
aminotransferase 700 nmol/sec- 
and/L, lactate dehydrogenase 
4,833 nmol/second/L, and 24-hour 
urine protein excretion 0.72 g. Pe- 
ripheral blood smear revealed pre- 
dominantly normal red blood cell 
morphology, numerous platelets, 
normal white blood cells without 
toxic granulations, and the pres- 
ence of several metamyelocytes. 
Reticulocyte count was 0.092. He- 
moglobin electrophoresis demon- 
strated the presence of sickle cell 
trait with 0.577 hemoglobin Al, 
0.030 hemoglobin Az, and 0.393 
hemoglobin S. No anomalous mi- 
gration of hemoglobin Al was 
noted. 
Chest radiography revealed a 
left-sided pleural effusion and left 
lower lobe atelectasis. Ultrasound 
showed an irregular fluid collection 
in the spleen that displaced most of 
the residual splenic tissue medial- 
ly, consistent with an intrasplenic 
hematoma or splenic infarction. 
Bone marrow examination re- 
vealed a hypercellular marrow with 
all cell lines present. Cytogenetic 
study demonstrated a normal 
46,XY chromosome pattern. 
The patient’s elevated white 
blood cell and platelet counts grad- 
ually returned to normal over the 
following several weeks without 
any further treatment. The pa- 
tient’s recovery was complete ex- 
cept for an episode of acute topha- 
ceous gout that occurred nine days 
after discharge and was treated 
with allopurinol, which resulted in 
resolution of symptoms. 
This is only the sixth known case 
of non-altitude-related splenic in- 
farction in an individual with sickle 
cell trait. Review of this case and 
the previously reported cases re- 
veals no single assessable variable 
that defines this group of patients. 
The patients included four males 
and two females, ranging from nine 
to 58 years of age. Two of the pa- 
tients were black, two were of Mid- 
dle Eastern descent, one was white 
of Sicilian descent, and one was 
Mexican. Two of the patients ap- 
parently had splenomegaly and 
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one was reported to have concur- 
rent hepatomegaly. The reported 
percentage of hemoglobin S pre- 
sent, in the four cases in which it 
was documented, ranged from 0.31 
to 0.42. The distribution of red cell 
hemoglobin between hemoglobin S 
and hemoglobin A in persons with 
sickle cell trait has been reported 
to range from 0.25 to 0.40 for hemo- 
globin S and 0.55 to 0.75 for hemo- 
globin A [2]. Five of the six patients 
presented with abdominal pain in 
the left upper quadrant, and the 
presenting hemoglobin levels 
ranged from 3.4 mmol/L to 9.0 
mmol/L. Other parameters were 
not consistently reported in these 
cases to allow comparisons or con- 
clusions to be made. Pleural effu- 
sions (particularly left-sided) and 
left lower lobe pulmonary infil- 
trates, as in our patient, have been 
described in patients with splenic 
infarctions [1,3]. 
The treatment of the reported 
patients with sickle cell trait and 
splenic infarction has relied pri- 
marily on supportive care. All of 
the reported cases, including ours, 
appear to have done well with such 
measures. The role of splenectomy 
in these patients remains unclear. 
At best, there does not appear to be 
any clear indication for splenecto- 
my in these patients, except possi- 
bly for patients who experience re- 
current episodes of splenic infarc- 
tion and for those with intractable 
persistent pain. 
Our case, and the five related 
cases reviewed, suggest that pa- 
tients presenting with findings 
consistent with splenic infarction 
should have sickle cell trait consid- 
ered as a predisposing factor in 
their differential diagnosis, even in 
the absence of high-altitude expo- 
sure. Sickle cell trait appears to be 
a relatively benign cause of splenic 
infarction. Treatment should be 
supportive and directed toward 
correcting any additional predis- 
posing conditions or subsequent 
complications. These cases do not 
contradict the findings that life ex- 
pectancy is normal in persons with 
sickle cell trait, as none of the re- 
ported patients with non-altitude- 
related splenic infarctions devel- 
oped significant sequelae. 
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Hyperkalemia is an important po- 
tential complication of pentami- 
dine isethionate treatment. The 
Physicians’ Desk Reference lists it 
as moderate, i.e., “non-life-threat- 
ening reaction,” occurring in only 
0.7% of patients treated, and de- 
spite the vast current literature on 
the subject, we found documenta- 
tion of this reaction in only two 
sources [1,2]. We now report a case 
of life-threatening hyperkalemia 
occurring in a patient treated for 
presumed Pneumocystis carinii 
pneumonia (PCP). 
A 38-year-old homosexual black 
man with a history of intravenous 
drug abuse presented with fever, 
chills, and drenching night sweats 
for two weeks. His temperature was 
39’C, pulse was 92/minute and reg- 
ular, and respirations were 24/min- 
ute. Generalized lymphadenopa- 
thy, bibasilar inspiratory rales, and 
hepatosplenomegaly were appar- 
ent on physical examination. Chest 
radiography revealed bilateral in- 
terstitial infiltrates, and resting ar- 
terial blood gas studies showed a 
pH of 7.51, carbon dioxide tension 
of 25 mm Hg, and oxygen tension of 
62 mm Hg. Gallium scan showed 
minimal activity at both lung 
bases, but bronchoscopy failed to 
identify an etiology for his pneu- 
monia. 
Treatment for presumed PCP 
was initiated with intramuscular 
pentamidine at the recommended 
4 mg/kg/day dose (220 mg in our 
patient). This resulted in prompt 
improvement of his dyspnea, fever, 
and sweats. During treatment, a 
modest deterioration in renal func- 
tion was observed as the creatinine 
level increased from 0.9 mg/dL to 
1.8 mg/dL and blood urea nitrogen 
(BUN) increased from 13 mg/dL to 
39 mg/dL over an eight-day period. 
During this time, the serum potas- 
sium level rose from a pretreat- 
ment value of 4.1 mEqiL to 5.5 
mEq/L by Day 4, 5.7 mEq/L by 
Day 7, and 7.6 mEq/L on Day 8, 
associated with peaked T waves 
and QRS complex widening. 
Treatment with pentamidine 
was stopped, electrocardiographic 
changes resolved, and serum potas- 
sium level fell after emergent treat- 
ment with intravenous calcium 
gluconate, insulin, dextrose, and 
oral sodium polystyrene sulfonate 
(KayexalateQ) . A second gradual 
increase in potassium to 6.5 mEq/L 
occurred over the five days follow- 
ing discontinuation of pentami- 
dine, and this too necessitated 
treatment with oral Kayexalate. 
Upon cessation of pentamidine, 
treatment with trimethoprim-sul- 
famethoxazole was started and 
continued for six days, so that the 
patient received a total of 14 days 
of antibiotic treatment. After three 
weeks of hospitalization, he was 
discharged in much improved con- 
dition with resolution of radio- 
graphic findings and hypoxia. The 
potassium level remained within 
normal limits (less than 4.9 mEq/ 
L) for five days prior to discharge 
without specific therapy. Weeks 
later, results of serologic testing in 
the patient returned positive for 
human immunodeficiency virus in- 
fection. 
We could find no obvious expla- 
nation for our patient’s hyperkale- 
mia. With the exception of acet- 
aminophen, pentamidine was the 
only medication he received before 
the development of maximal hy- 
perkalemia. Laboratory evidence 
of hemolysis was lacking, with a re- 
ticulocyte index of l%, stable he- 
matocrit, bilirubin, and lactic de- 
hydrogenase (LDH), and a normal 
serum haptoglobin level. The pa- 
tient never complained of pain at 
the intramuscular injection site nor 
was there was any sign of local tis- 
sue necrosis or abscess, or laborato- 
ry evidence of acidosis, ad rhab- 
domyolysis seemed unlikely with a 
stable LDH and aspartate amino- 
transferase @GOT) during hospi- 
talization. 
Renal insufficiency is the most 
frequent systemic side effect of 
pentamidine, seen in approximate- 
ly 25% of patients; it is usually mild 
and reversible and its mechanism 
is unknown [1,3]. The pharmacoki- 
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